JP2022537913A5 - - Google Patents
Info
- Publication number
- JP2022537913A5 JP2022537913A5 JP2021571935A JP2021571935A JP2022537913A5 JP 2022537913 A5 JP2022537913 A5 JP 2022537913A5 JP 2021571935 A JP2021571935 A JP 2021571935A JP 2021571935 A JP2021571935 A JP 2021571935A JP 2022537913 A5 JP2022537913 A5 JP 2022537913A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- aenh
- administered
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861758P | 2019-06-14 | 2019-06-14 | |
| US62/861,758 | 2019-06-14 | ||
| GB1910125.2 | 2019-07-15 | ||
| GBGB1910125.2A GB201910125D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of angioedema |
| PCT/GB2020/051441 WO2020249979A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of angioedema |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537913A JP2022537913A (ja) | 2022-08-31 |
| JP2022537913A5 true JP2022537913A5 (https=) | 2023-07-27 |
| JP7640474B2 JP7640474B2 (ja) | 2025-03-05 |
Family
ID=67700187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571935A Active JP7640474B2 (ja) | 2019-06-14 | 2020-06-15 | 血管性浮腫の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220226293A1 (https=) |
| EP (1) | EP3982961A1 (https=) |
| JP (1) | JP7640474B2 (https=) |
| KR (1) | KR20220024221A (https=) |
| CN (2) | CN118078821A (https=) |
| AR (1) | AR119159A1 (https=) |
| AU (1) | AU2020293616A1 (https=) |
| BR (1) | BR112021024447A2 (https=) |
| CA (1) | CA3142220A1 (https=) |
| CL (2) | CL2021003243A1 (https=) |
| GB (1) | GB201910125D0 (https=) |
| IL (1) | IL288612A (https=) |
| MA (1) | MA56188A (https=) |
| MX (1) | MX2021014558A (https=) |
| PH (1) | PH12021552967A1 (https=) |
| SG (1) | SG11202113375PA (https=) |
| TW (1) | TW202112371A (https=) |
| WO (1) | WO2020249979A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4480545A3 (en) | 2022-04-27 | 2025-02-26 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
| EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| PT3716952T (pt) * | 2017-11-29 | 2022-04-14 | Kalvista Pharmaceuticals Ltd | Formas de administração que incluem um inibidor de calicreína plasmática |
-
2019
- 2019-07-15 GB GBGB1910125.2A patent/GB201910125D0/en not_active Ceased
-
2020
- 2020-06-15 TW TW109120109A patent/TW202112371A/zh unknown
- 2020-06-15 SG SG11202113375PA patent/SG11202113375PA/en unknown
- 2020-06-15 WO PCT/GB2020/051441 patent/WO2020249979A1/en not_active Ceased
- 2020-06-15 CN CN202410143627.6A patent/CN118078821A/zh active Pending
- 2020-06-15 MX MX2021014558A patent/MX2021014558A/es unknown
- 2020-06-15 CA CA3142220A patent/CA3142220A1/en active Pending
- 2020-06-15 CN CN202080043658.4A patent/CN113993520A/zh active Pending
- 2020-06-15 AU AU2020293616A patent/AU2020293616A1/en not_active Abandoned
- 2020-06-15 MA MA056188A patent/MA56188A/fr unknown
- 2020-06-15 BR BR112021024447A patent/BR112021024447A2/pt unknown
- 2020-06-15 US US17/617,456 patent/US20220226293A1/en not_active Abandoned
- 2020-06-15 EP EP20734285.8A patent/EP3982961A1/en not_active Withdrawn
- 2020-06-15 JP JP2021571935A patent/JP7640474B2/ja active Active
- 2020-06-15 PH PH1/2021/552967A patent/PH12021552967A1/en unknown
- 2020-06-15 KR KR1020217043375A patent/KR20220024221A/ko not_active Withdrawn
- 2020-06-16 AR ARP200101682A patent/AR119159A1/es not_active Application Discontinuation
-
2021
- 2021-12-02 IL IL288612A patent/IL288612A/en unknown
- 2021-12-06 CL CL2021003243A patent/CL2021003243A1/es unknown
-
2023
- 2023-03-10 CL CL2023000699A patent/CL2023000699A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536287A5 (https=) | ||
| JP2022537913A5 (https=) | ||
| FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
| RU2012121185A (ru) | Фармацевтические композиции комбинаций ингибиторов дипептидилпептидазы-4 с пиоглитазоном | |
| AU2008302190A1 (en) | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors | |
| Ventafridda et al. | Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs | |
| US20250281397A1 (en) | Formulations of a plasma kallikrein inhibitor | |
| TW201414472A (zh) | Ｓｇｌｔ２抑制藥與抗高血壓藥之組合 | |
| CN115776885A (zh) | 用于治疗阿尔茨海默病和帕金森病的组合物和方法 | |
| TW202102209A (zh) | 低劑量三重組合調配物 | |
| CN102036669A (zh) | 用于治疗早泄的药物组合物 | |
| CN103599115B (zh) | 一种组合物在制备抗癫痫药物中的应用 | |
| CN1509178A (zh) | 一种包括溶血磷脂酸的药用组合物 | |
| US20040087644A1 (en) | Pharmaceutical composition in capsules that comprises a non-steroidal antiinflamatory and an optiate analgesic for handling pain | |
| US20070093520A1 (en) | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject | |
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| Di Pierro et al. | Clinical effectiveness of a highly standardized and bioavailable mixture of flavonoids and triterpenes in the management of acute hemorroidal crisis | |
| CN105079012A (zh) | 天麻素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| US20240122956A1 (en) | Application of Naringin Combined with Rapamycin in Preparation of Medications for Treating Hyperlipidemia | |
| US20240423961A1 (en) | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones | |
| CN112569356B (zh) | 一种含有利尿剂的药物组合物 | |
| JP5440502B2 (ja) | 過敏性腸症候群の治療方法 | |
| AU2011273907B2 (en) | Tapentadol for use in the treatment of Irritable Bowel Syndrome | |
| CN112569357B (zh) | 双重内皮素受体拮抗剂与利尿剂的组合物 | |
| JP2009235093A (ja) | 鼻炎用医薬組成物 |